RANDOMIZED STUDY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HIGH-RISK LYMPHOID MALIGNANCIES
Ra. Stahel et al., RANDOMIZED STUDY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HIGH-RISK LYMPHOID MALIGNANCIES, Journal of clinical oncology, 12(9), 1994, pp. 1931-1938
Purpose: The aim of this prospective randomized trial was to examine t
he efficacy and safety of filgrastim after high-dose chemotherapy and
autologous bone marrow transplantation (ABMT) Patients and Methods: Pa
tients with poor-risk non-Hodgkin's lymphoma or relapsed Hodgkin's dis
ease were treated in a randomized, open-label trial to study the use o
f filgrastim as on adjunct to high-dose chemotherapy and ABMT. Of 43 a
ssessable patients, 19 were randomized to receive filgrastim by contin
uous subcutaneous infusion at a dose of 10 mu g/kg/d, 10 to filgrastim
20 mu g/kg/d, and 14 to a parallel control group that received no fil
grastim after ABMT. Results: For all filgrastim-treated patients analy
zed together, the median time to neutrophil recovery greater than or e
qual to 0.5 x 10(9)/L after the day of ABMT was significantly accelera
ted to 10 days compared with 18 days in control patients (P = .0001).
The median number of platelet transfusions was identical in both group
s. Clinical parameters, including the median number of days with fever
(1 v 4, P = .0418) and neutropenic fever (5 v 13.5, P = .0001) were s
ignificantly shorter in the filgrastim than in the control group. The
number of days on intravenous antibiotics and duration of hospitalizat
ion were also shorter in the treated groups; however, the differences
did not reach statistical significance. For patients treated with the
two different dose levels of filgrastim, the neutrophil recovery and c
linical results were similar. Filgrastim-associated toxicity appeared
to be minimal, with five adverse events considered at least possibly r
elated to filgrastim: two in the higher-dose group and three in the lo
wer-dose group. All of these were rated moderate, except one case of s
evere bone pain that did not preclude continued filgrastim treatment a
t a lower dose. Survival and relapse-free survival were similar for co
ntrol and filgrastim-treated patients. Conclusion: Taken together, the
results of this first randomized study support the role of filgrastim
given as an adjunct to ABMT in accelerating neutrophil recovery, as w
ell as in reducing treatment-related morbidity and overall duration of
the treatment procedure. (C) 1994 by American Society of Clinical Onc
ology.